KLDO (Kaleido Biosciences) Ending Cash Position: $40.64 Mil (As of Dec. 2021)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Kaleido Biosciences Ending Cash Position?

Kaleido Biosciences KLDO Ending Cash Position is $40.64 Mil as of Dec. 2021.

Kaleido Biosciences's Ending Cash Position for the quarter that ended in Dec. 2021 was $40.64 Mil.

Kaleido Biosciences's quarterly Ending Cash Position declined from Jun. 2021 ($74.14 Mil) to Sep. 2021 ($57.82 Mil) and declined from Sep. 2021 ($57.82 Mil) to Dec. 2021 ($40.64 Mil).

Kaleido Biosciences's annual Ending Cash Position declined from Dec. 2019 ($73.53 Mil) to Dec. 2020 ($48.38 Mil) and declined from Dec. 2020 ($48.38 Mil) to Dec. 2021 ($40.64 Mil).

Kaleido Biosciences Ending Cash Position Related Terms

Kaleido Biosciences Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Kaleido Biosciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kaleido Biosciences Ending Cash Position Chart

Kaleido Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Ending Cash Position
Get a 7-Day Free Trial 28.68 78.27 73.53 48.38 40.64

Kaleido Biosciences Quarterly Data
Dec16 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.38 94.52 74.14 57.82 40.64

Kaleido Biosciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Kaleido Biosciences's Ending Cash Position for the fiscal year that ended in Dec. 2021 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=48.383+-7.748
=40.64

Kaleido Biosciences's Ending Cash Position for the quarter that ended in Dec. 2021 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=57.818+-17.183
=40.64

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $40.64 Mil mean?
Kaleido Biosciences (KLDO) has a Ending Cash Position of $40.64 Mil as of Dec. 2021. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Kaleido Biosciences and its competitors.
Is Kaleido Biosciences' Ending Cash Position too high?
Kaleido Biosciences' current Ending Cash Position is $40.64 Mil.
How does Kaleido Biosciences' Ending Cash Position compare to NPTX and GSTC?
Kaleido Biosciences' Ending Cash Position of $40.64 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Kaleido Biosciences and its competitors. Kaleido Biosciences's current Ending Cash Position is $40.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaleido Biosciences stock overvalued right now?
Kaleido Biosciences (KLDO) has a current Ending Cash Position of $40.64 Mil. The current Ending Cash Position is $40.64 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Kaleido Biosciences (KLDO), the current Ending Cash Position is $40.64 Mil as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kaleido Biosciences Business Description

Address 65 Hayden Avenue, Lexington, MA, USA, 02421
Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome.